



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstone Michael V. Messinger Judith U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Albert L. Ferro\* Donald R. Banowit Petre A. Jackman Teresa U. Medler Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Eldora Ellison Floyd Thomas C. Fiala Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Christine M. Lhulier Rea Lynn P. Guest George S. Bardmesser Daniel A. Klein\* Jason D. Eisenberg Michael D. Specht Andrea J. Kamage Tracy L. Muller\* LuAnne M. DeSantis Ann E. Summerfield Aric W. Ledford\* Helene C. Carlson Timothy A. Doyle\* Gaby L. Longsworth Lori A. Gordon\* Nicole D. Dretar\*

Ted J. Ebersole Jyoti C. Iyer\* Laura A. Vogel Registered Pate Karen R. Marko Nancy J. Leith

Registered Patent Agents • Karen R. Markowicz Nancy J. Leith Matthew J. Dowd Aaron L. Schwartz Katrina Yujian Pel Quach Bryan L. Skelton Robert A. Schwartzman Teresa A. Colella Jeffrey S. Lundgren Victoria S. Rutherford Michelle K. Holoubek Robert H. DeSelms Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse Michael G. Penn Christopher J. Walsh

<u>Of Counsel</u> Kenneth C. Bass III Evan R. Smith Marvin C. Guthrie

\*Admitted only in Maryland \*Admitted only in Virginia •Practice Limited to Federal Agencies

December 15, 2004

WRITER'S DIRECT NUMBER: (202) 772-8615 INTERNET ADDRESS: FRANKC@SKGF.COM

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/052,817; Filed: January 23, 2002

For: Alpha-2-Macroglobulin Therapies and Drug Screening Methods for

Alzheimer's Disease

Inventors:

Tanzi et al.

Our Ref:

0609.4460005/TJS/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Amendment and Reply Under 37 C.F.R. § 1.111; and
- 2. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox P.L.L.c.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents December 15, 2004 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Frank R. Cottingham Attorney for Applicants Registration No. 50,437

FRC/pcd Encls.

344516v1

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

In re application of:

TANZI et al.

Appl. No. 10/052,817

Filed: January 23, 2002

For:

**Alpha-2-Macroglobulin Therapies** 

and Drug Screening Methods for

Alzheimer's Disease

Confirmation No.: 4182

Art Unit: 1632

Examiner: Woitach, J.

Atty. Docket: 0609.4460005/TJS/FRC

## Amendment and Reply Under 37 C.F.R. § 1.111

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated September 16, 2004, Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, a complete listing of all of the claims:
  - in ascending order;
  - with status identifiers; and
  - with markings in the currently amended claims;
- (D) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.